| 2387 | Humans |
| 1618 | Male |
| 1508 | Female |
| 1180 | Middle Aged |
| 1138 | Parkinson Disease |
| 1083 | Aged |
| 782 | Adult |
| 359 | Aged, 80 and over |
| 337 | Severity of Illness Index |
| 327 | Neurologic Examination |
| 279 | Antiparkinson Agents |
| 258 | Levodopa |
| 215 | Magnetic Resonance Imaging |
| 214 | Brain |
| 208 | Adolescent |
| 206 | Treatment Outcome |
| 205 | Dystonia |
| 204 | Animals |
| 182 | Movement Disorders |
| 159 | Tremor |
| 157 | Neuropsychological Tests |
| 152 | Dose-Response Relationship, Drug |
| 146 | Diagnosis, Differential |
| 136 | Risk Factors |
| 135 | Follow-Up Studies |
| 134 | Retrospective Studies |
| 133 | Double-Blind Method |
| 132 | Child |
| 125 | Electromyography |
| 120 | Essential Tremor |
| 119 | Huntington Disease |
| 118 | Parkinsonian Disorders |
| 117 | Deep Brain Stimulation |
| 116 | Cognition Disorders |
| 113 | Questionnaires |
| 110 | Case-Control Studies |
| 105 | Disability Evaluation |
| 104 | Dyskinesia, Drug-Induced |
| 104 | Disease Progression |
| 102 | Time Factors |
| 98 | Reproducibility of Results |
| 89 | Genetic Predisposition to Disease |
| 89 | Dystonic Disorders |
| 88 | Videotape Recording |
| 87 | Age of Onset |
| 85 | Young Adult |
| 85 | Mutation |
| 84 | Genotype |
| 82 | Drug Therapy, Combination |
| 78 | Psychomotor Performance |
| 78 | Dopamine |
| 78 | Corpus Striatum |
| 76 | Dementia |
| 73 | United States |
| 73 | Substantia Nigra |
| 73 | Functional Laterality |
| 71 | Drug Administration Schedule |
| 70 | Carbidopa |
| 69 | Neurons |
| 68 | Tourette Syndrome |
| 68 | Chorea |
| 67 | Disease Models, Animal |
| 66 | Torticollis |
| 66 | Phenotype |
| 66 | Cohort Studies |
| 66 | Activities of Daily Living |
| 65 | alpha-Synuclein |
| 65 | Parkinson Disease, Secondary |
| 65 | DNA Mutational Analysis |
| 65 | Child, Preschool |
| 65 | Analysis of Variance |
| 64 | Cerebral Cortex |
| 64 | Brain Mapping |
| 64 | Age Factors |
| 63 | Myoclonus |
| 63 | Antipsychotic Agents |
| 61 | Globus Pallidus |
| 60 | Nerve Tissue Proteins |
| 58 | Restless Legs Syndrome |
| 58 | Movement |
| 57 | Psychiatric Status Rating Scales |
| 57 | Longitudinal Studies |
| 56 | Quality of Life |
| 56 | Prospective Studies |
| 56 | History, 20th Century |
| 56 | Basal Ganglia |
| 55 | Prevalence |
| 55 | Posture |
| 55 | Botulinum Toxins |
| 54 | Muscle, Skeletal |
| 54 | Motor Activity |
| 52 | Dominance, Cerebral |
| 51 | Electroencephalography |
| 51 | Dopamine Agents |
| 51 | Cross-Sectional Studies |
| 50 | Subthalamic Nucleus |
| 50 | Botulinum Toxins, Type A |
| 50 | Atrophy |
| 49 | Pedigree |
| 48 | Motor Skills |
| 47 | Gait |
| 46 | Supranuclear Palsy, Progressive |
| 45 | Injections, Intramuscular |
| 44 | Protein-Serine-Threonine Kinases |
| 44 | Point Mutation |
| 43 | Pilot Projects |
| 43 | Dopamine Agonists |
| 43 | Depression |
| 42 | Family Health |
| 41 | Statistics, Nonparametric |
| 41 | Mental Status Schedule |
| 40 | Multiple System Atrophy |
| 39 | Reaction Time |
| 39 | Gene Frequency |
| 38 | Drug Combinations |
| 37 | Rats |
| 37 | Postural Balance |
| 37 | Incidence |
| 37 | Image Processing, Computer-Assisted |
| 37 | Cerebellum |
| 37 | Basal Ganglia Diseases |
| 36 | Sensitivity and Specificity |
| 36 | Putamen |
| 36 | Nerve Degeneration |
| 36 | Clinical Trials as Topic |
| 35 | Ubiquitin-Protein Ligases |
| 35 | Receptors, Dopamine |
| 35 | Genetic Testing |
| 35 | Electrodes, Implanted |
| 34 | Thalamus |
| 34 | Reference Values |
| 34 | Predictive Value of Tests |
| 33 | Tomography, X-Ray Computed |
| 33 | Sex Factors |
| 32 | Psychometrics |
| 32 | Mice |
| 32 | Hypokinesia |
| 32 | Gait Disorders, Neurologic |
| 32 | Anticonvulsants |
| 31 | Neuroprotective Agents |
| 31 | History, 19th Century |
| 31 | Hand |
| 31 | Cognition |
| 31 | Alleles |
| 30 | Positron-Emission Tomography |
| 30 | Polymorphism, Single Nucleotide |
| 30 | Odds Ratio |
| 30 | Lewy Bodies |
| 30 | Exons |
| 30 | Comorbidity |
| 30 | Biomechanical Phenomena |
| 29 | Neuromuscular Agents |
| 29 | Hallucinations |
| 29 | Dyskinesias |
| 28 | Tomography, Emission-Computed, Single-Photon |
| 28 | Statistics as Topic |
| 28 | Risk |
| 28 | Regression Analysis |
| 28 | Neural Pathways |
| 28 | Lewy Body Disease |
| 28 | Alzheimer Disease |
| 27 | Blepharospasm |
| 26 | Sleep Disorders |
| 26 | Psychotic Disorders |
| 26 | Neurodegenerative Diseases |
| 26 | Electric Stimulation Therapy |
| 26 | Caudate Nucleus |
| 26 | Ataxia |
| 25 | Trinucleotide Repeats |
| 25 | Tomography, Emission-Computed |
| 25 | Neurology |
| 25 | Mental Disorders |
| 25 | Infant |
| 25 | Arm |
| 24 | Trinucleotide Repeat Expansion |
| 24 | Selegiline |
| 24 | History, 21st Century |
| 24 | Handwriting |
| 24 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 23 | Stereotaxic Techniques |
| 23 | Smoking |
| 23 | Polymorphism, Genetic |
| 23 | Obsessive-Compulsive Disorder |
| 23 | Observer Variation |
| 23 | Depressive Disorder |
| 23 | Demography |
| 23 | Cross-Over Studies |
| 22 | Syndrome |
| 22 | Polysomnography |
| 22 | Muscle Rigidity |
| 22 | Genetic Linkage |
| 22 | Gene Expression |
| 22 | Chi-Square Distribution |
| 22 | Anti-Dyskinesia Agents |
| 21 | Walking |
| 21 | Signal Processing, Computer-Assisted |
| 21 | Proportional Hazards Models |
| 21 | Databases, Factual |
| 21 | Confidence Intervals |
| 20 | tau Proteins |
| 20 | Polymerase Chain Reaction |
| 20 | Muscle Contraction |
| 20 | Fatal Outcome |
| 20 | Epilepsies, Myoclonic |
| 20 | Clozapine |
| 20 | Brain Stem |
| 19 | Tic Disorders |
| 19 | Stereotyped Behavior |
| 19 | Spinocerebellar Degenerations |
| 19 | Postoperative Complications |
| 19 | Outcome Assessment (Health Care) |
| 19 | Olfaction Disorders |
| 19 | Nuclear Proteins |
| 19 | Logistic Models |
| 19 | Fingers |
| 19 | Chromosome Aberrations |
| 19 | Benzothiazoles |
| 19 | Attention Deficit Disorder with Hyperactivity |
| 19 | Aging |
| 18 | Spinal Cord |
| 18 | Randomized Controlled Trials as Topic |
| 18 | RNA, Messenger |
| 18 | Prognosis |
| 18 | Glycine |
| 18 | Genetic Variation |
| 18 | Biological Markers |
| 17 | Motor Neurons |
| 17 | Motor Cortex |
| 17 | Locomotion |
| 17 | Leg |
| 17 | Indoles |
| 17 | Haplotypes |
| 17 | Genes, Dominant |
| 17 | Dopamine Plasma Membrane Transport Proteins |
| 17 | Cerebellar Ataxia |
| 17 | Attention |
| 17 | Anxiety |
| 16 | Video Recording |
| 16 | Tyrosine 3-Monooxygenase |
| 16 | Tetrabenazine |
| 16 | Spain |
| 16 | REM Sleep Behavior Disorder |
| 16 | Pain |
| 16 | Neurosurgical Procedures |
| 16 | Neck Muscles |
| 16 | Music |
| 16 | Molecular Chaperones |
| 16 | Frontal Lobe |
| 16 | Electric Stimulation |
| 16 | Cerebral Infarction |
| 16 | Carrier Proteins |
| 16 | Amantadine |
| 15 | Pain Measurement |
| 15 | Occupational Diseases |
| 15 | Health Surveys |
| 15 | Fragile X Syndrome |
| 15 | Evoked Potentials, Motor |
| 15 | Combined Modality Therapy |
| 15 | Chromosome Mapping |
| 15 | Baclofen |
| 15 | Autonomic Nervous System Diseases |
| 14 | Thalamic Nuclei |
| 14 | Terminology as Topic |
| 14 | Spinocerebellar Ataxias |
| 14 | ROC Curve |
| 14 | Psychophysiologic Disorders |
| 14 | Mesencephalon |
| 14 | Macaca fascicularis |
| 14 | Indans |
| 14 | Hyperkinesis |
| 14 | Fluorodeoxyglucose F18 |
| 14 | Dihydroxyphenylalanine |
| 14 | Community Health Planning |
| 14 | Autopsy |
| 13 | Transcranial Magnetic Stimulation |
| 13 | Tics |
| 13 | Synucleins |
| 13 | Receptors, Dopamine D2 |
| 13 | Periodicity |
| 13 | Pergolide |
| 13 | Microelectrodes |
| 13 | Membrane Glycoproteins |
| 13 | Heterozygote Detection |
| 13 | Genetic Markers |
| 13 | European Continental Ancestry Group |
| 13 | Drug Tolerance |
| 13 | Dopamine Antagonists |
| 13 | Central Nervous System Stimulants |
| 13 | Bromocriptine |
| 13 | Brain Diseases |
| 13 | Administration, Oral |
| 12 | Thiazoles |
| 12 | Recurrence |
| 12 | Rats, Sprague-Dawley |
| 12 | Radiopharmaceuticals |
| 12 | Mood Disorders |
| 12 | Monoamine Oxidase Inhibitors |
| 12 | Minnesota |
| 12 | Machado-Joseph Disease |
| 12 | Isometric Contraction |
| 12 | Hepatolenticular Degeneration |
| 12 | Health Status |
| 12 | Genetic Therapy |
| 12 | Gene Expression Regulation |
| 12 | Europe |
| 12 | Dysarthria |
| 12 | Dibenzothiazepines |
| 12 | Diagnostic and Statistical Manual of Mental Disorders |
| 12 | Cross-Cultural Comparison |
| 12 | Conversion Disorder |
| 12 | Chromosome Disorders |
| 12 | Blinking |
| 12 | Athetosis |
| 12 | Accidental Falls |
| 11 | gamma-Aminobutyric Acid |
| 11 | Ventral Thalamic Nuclei |
| 11 | Single-Blind Method |
| 11 | Serotonin Uptake Inhibitors |
| 11 | Serine |
| 11 | Sensation Disorders |
| 11 | Schizophrenia |
| 11 | Psychomotor Disorders |
| 11 | Piracetam |
| 11 | Neurotoxins |
| 11 | Neural Inhibition |
| 11 | Nerve Net |
| 11 | Mitochondria |
| 11 | Memory |
| 11 | Magnetic Resonance Spectroscopy |
| 11 | Intracellular Signaling Peptides and Proteins |
| 11 | Infusions, Intravenous |
| 11 | Hypoxia, Brain |
| 11 | Genetic Association Studies |
| 11 | Fragile X Mental Retardation Protein |
| 11 | Exercise |
| 11 | Ethnic Groups |
| 11 | Encephalitis |
| 11 | Dystonia Musculorum Deformans |
| 11 | Delayed-Action Preparations |
| 11 | DNA-Binding Proteins |
| 11 | DNA Primers |
| 11 | Cues |
| 11 | Arousal |
| 11 | Apomorphine |
| 11 | Algorithms |
| 10 | Verbal Behavior |
| 10 | Stereotypic Movement Disorder |
| 10 | Speech Disorders |
| 10 | Serotonin |
| 10 | Receptors, N-Methyl-D-Aspartate |
| 10 | Psychoses, Substance-Induced |
| 10 | Proprioception |
| 10 | Oxidative Stress |
| 10 | Oncogene Proteins |
| 10 | Olivopontocerebellar Atrophies |
| 10 | New York City |
| 10 | Muscle Relaxants, Central |
| 10 | Monoamine Oxidase |
| 10 | Membrane Transport Proteins |
| 10 | Mass Screening |
| 10 | Jews |
| 10 | International Cooperation |
| 10 | Homovanillic Acid |
| 10 | Hemifacial Spasm |
| 10 | Hand Strength |
| 10 | Friedreich Ataxia |
| 10 | Feasibility Studies |
| 10 | Fatigue |
| 10 | Factor Analysis, Statistical |
| 10 | Facial Muscles |
| 10 | Exhibits as Topic |
| 10 | Diagnosis, Computer-Assisted |
| 10 | Deglutition Disorders |
| 10 | Compulsive Behavior |
| 10 | Cocaine |
| 10 | Chronic Disease |
| 10 | Biomedical Research |
| 10 | Anxiety Disorders |
| 10 | Affect |
| 9 | Weight-Bearing |
| 9 | Voice Disorders |
| 9 | Ubiquitin |
| 9 | Thalamic Diseases |
| 9 | Substance Withdrawal Syndrome |
| 9 | Stroke |
| 9 | Somatosensory Cortex |
| 9 | Somatoform Disorders |
| 9 | Rest |
| 9 | Purkinje Cells |
| 9 | Protein Kinases |
| 9 | Pregnancy |
| 9 | Placebos |
| 9 | Photic Stimulation |
| 9 | Patient Selection |
| 9 | Patient Satisfaction |
| 9 | Ocular Motility Disorders |
| 9 | Neck |
| 9 | Muscles |
| 9 | Muscle Cramp |
| 9 | Motor Neuron Disease |
| 9 | Linear Models |
| 9 | Intellectual Disability |
| 9 | Injections, Subcutaneous |
| 9 | Impulse Control Disorders |
| 9 | Imaging, Three-Dimensional |
| 9 | Heterozygote |
| 9 | Heart Rate |
| 9 | Glutamic Acid |
| 9 | Glucose |
| 9 | Germany |
| 9 | Gastrointestinal Diseases |
| 9 | France |
| 9 | Fourier Analysis |
| 9 | Executive Function |
| 9 | Energy Metabolism |
| 9 | Electrocardiography |
| 9 | Diseases in Twins |
| 9 | Data Interpretation, Statistical |
| 9 | Constipation |
| 9 | Clonazepam |
| 9 | Chromosome Deletion |
| 9 | Cerebral Palsy |
| 9 | Caregivers |
| 9 | Biopsy |
| 9 | Autoantibodies |
| 9 | Apraxias |
| 9 | Antioxidants |
| 9 | Antidepressive Agents |
| 9 | Amyloid beta-Peptides |
| 8 | Wrist |
| 8 | Visual Perception |
| 8 | Tongue |
| 8 | Smell |
| 8 | Sex Distribution |
| 8 | Reverse Transcriptase Polymerase Chain Reaction |
| 8 | Rats, Inbred Strains |
| 8 | Pyramidal Tracts |
| 8 | PubMed |
| 8 | Psychomotor Agitation |
| 8 | Proteins |
| 8 | Piperazines |
| 8 | Orientation |
| 8 | Nitriles |
| 8 | Neuronal Plasticity |
| 8 | Neuroglia |
| 8 | Mutation, Missense |
| 8 | Muscle Weakness |
| 8 | Microsatellite Repeats |
| 8 | Mice, Inbred C57BL |
| 8 | Medical Records |
| 8 | MPTP Poisoning |
| 8 | Long-Term Care |
| 8 | Linkage Disequilibrium |
| 8 | Kaplan-Meier Estimate |
| 8 | Iron |
| 8 | Hydroxyindoleacetic Acid |
| 8 | Hippocampus |
| 8 | Head |
| 8 | Guidelines as Topic |
| 8 | Gene Deletion |
| 8 | Fetal Tissue Transplantation |
| 8 | Ergolines |
| 8 | Environmental Exposure |
| 8 | Drug Interactions |
| 8 | Disorders of Excessive Somnolence |
| 8 | Diffusion Magnetic Resonance Imaging |
| 8 | Data Collection |
| 8 | DNA, Mitochondrial |
| 8 | Coffee |
| 8 | Cerebellar Diseases |
| 8 | Catechols |
| 8 | Catechol O-Methyltransferase Inhibitors |
| 8 | Brain Neoplasms |
| 8 | Brain Injuries |
| 8 | Bipolar Disorder |
| 8 | Autoimmune Diseases |
| 8 | Aspartic Acid |
| 8 | Arginine |
| 8 | Apolipoproteins E |
| 8 | Akathisia, Drug-Induced |
| 8 | Action Potentials |
| 8 | Acoustic Stimulation |
| 7 | Thiophenes |
| 7 | Tetrahydronaphthalenes |
| 7 | Teaching |
| 7 | Task Performance and Analysis |
| 7 | Survival Analysis |
| 7 | Stress, Psychological |
| 7 | Sickness Impact Profile |
| 7 | Siblings |
| 7 | Sex Characteristics |
| 7 | Sensory Thresholds |
| 7 | Pyridines |
| 7 | Psychological Tests |
| 7 | Postoperative Period |
| 7 | Postmortem Changes |
| 7 | Personality Inventory |
| 7 | Peripheral Nerves |
| 7 | Parietal Lobe |
| 7 | Pantothenate Kinase-Associated Neurodegeneration |
